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We present the incidence and the immunologic characteristics of acute lymphoblastic leukemia (ALL) subsets in Moroccan
children. We studied 279 unselected patients below the age of 18 years with newly diagnosed ALL. Cases were classiﬁed according
to immunophenotype: 216 (77.42%) precursor B-cell phenotype (pB-cell), mature B-cell in 4 (1.43%), and T-cell in 59 (21.15%)
cases. The subclassiﬁcation using the CD10 antibody revealed 197 cases pB-ALL CD10+ (91.2%) and 9 cases T-ALL CD10+
(19.2%). The age distribution showed a peak in incidence between 3 and 5 years among the pB-cell ALLs subtype. There was a
signiﬁcantlyhigherfrequencyofmalesintheT-ALLsubset(M/Fratio:2.93:1)andmorefemalesintheT-ALLCD10+subsetwhen
compared with the T-ALL CD10– subset. All tested pB-cell-lineage ALLs expressed CD19, CD79a, and surface CD22, terminal
deoxynucleotidyl transferase (TdT) was detectable in 89.9% of cases, and cells in 74.1% of cases express CD34. All tested T-lineage
ALL cells have surface CD7 and cytoplasmic CD3 (cCD3) antigens, CD5 was found in 98.2% cases, and 70.5% express TdT. CD1a,
surface CD3 (sCD3), and CD4 are detected in more than 80% of cases; this frequency is higher than the 45% generally observed.
Myeloid antigens occur more frequently and were expressed in 124 (57.4%) of pB-cell-ALL cases and 20 (33.9%) of T-cell ALL
cases. Our results show that the distribution of ALLs in Moroccan children is similar with the general distribution pattern in
developed countries except for the high frequency of T-ALL phenotype. The phenotypic proﬁles of our patients are close to those
reported in literature for B-lineage ALLs; for the T-cell ALL subgroup, the blast cells express more CD1a, surface CD3, and CD4
while expressing less TdT. The high frequency of CD1a expression resulted in an excess of the common thymocyte subtype.
Copyright © 2009 Fatima Bachir et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Acute lymphoblastic leukemia (ALL) is the most common
form of leukemia in children; 75% of cases occur in children
under six years of age [1]. The peak in incidence is between
the ages of two and ﬁve, and the vast majority of ALL cases
(80%–85%) are of precursor B-lineage [1, 2]. Approximately
80% of children with B-ALL appear to be cured [1].
In Morocco, there are two dedicated pediatric oncology
units, and compared to that seen in developed countries,
treatment is less successful [3, 4] .T h es u r v i v a lr a t ea f t e r
treatmentforALLchildreninMoroccoislessthan40%,even
in specialized centers [3]. In 2003, the St. Jude International
Outreach Program became a partner with the two pediatric
oncology units to improve the outcome of Moroccan chil-
dren with malignancies. In ALL, causes of treatment failure
including abandonment of therapy, suboptimal supportive
careandlackofuniformtreatmentguidelines[4,5]appeared
tobethemostcommon.However,therewasapossibilitythat
the subtypes of pediatric ALL in Morocco could include an
excess of high-risk leukemia subtypes.
Since December 2003, the National Hygiene Institute
laboratory has become the referral ﬂow cytometry service
for acute leukemia for the two pediatric oncology units. The
main goal is to have a better survival rate by developing a
specializedmultidisciplinarycareteamsandtheintroduction
of a uniform national treatment protocol (MARALLl 2006).2 International Journal of Pediatrics
To determine the distribution of ALL subtypes in these
two pediatric oncology units, we reviewed the results of cases
submitted for immunophenotypic analysis.
2. Patientsand Methods
2.1. Patients. From October 2003, to May 2007, 279 con-
secutive children (114 females, 165 males) below the age
of 18 years with newly diagnosed ALL were recruited from
the Onco-haematology-Pediatric service of the University
Hospitals of Rabat and Casablanca. These hospitals are
the main referral pediatric centers for leukemia patients in
Morocco [6, 7].
The diagnosis of ALL was based on morphologic,
cytochemical criteria of the French-American-British (FAB)
Cooperative Working Group and ﬂow cytometric analysis.
Using these criteria, 144 cases were classiﬁed as L1, 101 cases
as L2, 4 cases as L3. 30 cases were not classiﬁed as FAB
subtypes.
2.2. Flow Cytometry. The immunophenotyping was per-
formed at the National Hygiene Institute laboratory on
bone marrow aspirate or peripheral blood samples collected
in EDTA according to a two-step strategy using panels of
monoclonal antibodies based on the European Group for
the Immunological Characterization of Leukemia (EGIL)
[8] and St. Jude Children’s Research Hospital strategies
[9]. Immunophenotypic characterization consisted of two
consecutive steps (Table 1). According to the results obtained
at the initial screening, the second level of investigation was
assessed. The second panel is designed to identify stage of
diﬀerentiation, prognosis features or aberrant phenotypes
for monitoring minimal residual disease [10, 11].
The reactivity with ﬂuorescent conjugated monoclonal
antibodies directed against lymphoid and myeloid associated
antigens was evaluated on the surface of leukemic cells.
The intracytoplasmic Immunoglobin (Ig), CD3, CD79a
and myeloperoxidase (MPO) antigens, as well as nuclear
terminal deoxynucleotidyl transferase (TdT) staining, were
evaluated by ﬂuorescent conjugated monoclonal antibodies
after ﬁxation and permeabilization of leukemic cell. Stained
cells were analyzed by ﬂow cytometry on a three-color
FACSCallibur ﬂow cytometer (Becton Dickinson Immuno-
cytometer Systems) which was calibrated with a set of
standardized beads (Becton Dickinson Calibrate 3). Blasts
initially were gated for analysis by using CD45 versus side
scatter, according to the gating strategy [12].
Leukemic samples were considered positive for a partic-
ular antigen if 20% or more of leukemic cells reacted with a
particular antibody.
2.3. Immunological Classiﬁcation and Nomenclature. The
cases were classiﬁed in three main ALL immunological
subtypes: mature B-cell ALL, precursor B-cell ALL (pB-
cell ALL), and T-cell ALL [1, 13]. A case was consid-
ered mature B-cell ALL if the cells expressed surface
immunoglobulin (sIg) with Kappa or lambda light chains.
Precursor B-cell ALLs include 3 immunological subtypes’


























early pre-B (CD19+, CD22+, CD79a and lack cytoplas-
mic immunoglobulin μ (cμ) and surface immunoglobu-
lin), pre-B (CD19+, CD22+, CD79a+ exhibit cytoplasmic
immunoglobulin μ without detectable surface immunoglob-
ulin) and transitional pre-B (CD19+, CD22+, CD79a and
express both cytoplasmic immunoglobulin μ and surface
immunoglobulin) without Kappa or Lambda light chains
[14]. T-cell ALL can also be separated into 3 maturational
stages, deﬁned as follows: proT (cyCD3+, CD7+, CD1a−,
sCD3−) common thymocyte (cyCD3+, CD7+, CD1a+) and
mature thymocyte (cyCD3+, CD7+, CD1a−,s C D 3 + ) .
2.4.StatisticalAnalysis. Associationbetweentheincidenceof
immunologic phenotype and clinical and biologic features
was examined and tested by chi-square test using the Excel
Stat software.
3. Results
The study group comprised 279 newly diagnosed and
untreated acute lymphoblastic leukemia cases (<18 years).
There were 114 females and 165 males with a male/female
ratio of 1.45 : 1. Immunophenotypic analysis showed that
the precursor B-cell phenotype was encountered in 216
(77.42%), mature B-cell in 4 (1.43%) and T-cell in 59
(21.15%) cases. The patients’ characteristics are summarized
in Table 2. The distribution of immunological ALL subtypes
is clearly inﬂuenced by clinical features. Compared with pB-
cell ALL, male sex (P = .008), older age (P = .048), higher
leukocyte count (P<. 0001) and mediastinal mass (P<
.0001) seem to be the typical features of T-cell ALL subtype.
The age distribution of the diﬀerent ALL subtypes
(Figure 1) shows that pB-cell ALLs patients were younger
with peak in incidence between 3 and 5 years. There was a
trend for patients with T-cell ALL to have a more advanced
age.International Journal of Pediatrics 3
Table 1: Panel of Monoclonal Antibodies used in this study for immunophenotypic acute leukemia characterization.
B-cell markers T-cell markers Myeloid markers No speciﬁc markers
First step CD79a, CD19, CD22 sCD3, cyCD3, CD7 CD13, CD33, anti-MPO CD45
Second step cytIg, sIg CD1a, CD4, CD5, CD8 CD117, CD41, CD61, GlycoA CD34, DR, TdT, CD10
sIg: surface immunoglobulin, cyIg: cytoplasmic immunoglobulin, sCD3: surface CD3, cyCD3: cytoplasmic CD3, MPO: myeloperoxidase, Glyco A:
Glycophorin A, DR: HLA-DR: antigen, TdT: terminal deoxynucleotidyl transferase.
3.1. B-Cell-Lineage ALLs
3.1.1. Precursor B-Cell. 216 children with pB-cell phenotype
were studied. There were 99 females and 117 males with a
male/female ratio of 1.18 : 1 and median age of 6 years.
All tested pB-cell-lineage ALLs expressed CD19. Almost
all cases have cytoplasmic CD79a and surface CD22, the
CD20 is present in more than one-half (54.2%) of cases
tested for this antigen. CD10, terminal deoxynucleotidyl
transferase (TdT), HLA-DR, and CD45 were detectable in
91.2%, 89.8%, 98.1%, and 87% of cases, respectively, and
cells in more than 74% of cases express CD34. In 40% of
CD34positivescases,CD45isnegativeorweak.CD13and/or
CD33 occur more frequently (57.4%). CD7 is also present in
few cases (3.2%).
Immunologic subclassiﬁcation of 58 pB cell ALLs cases
tested for cytoplasmic and surface immunoglolobin since
August 2006 revealed 40 early pre-B (69%), 16 pre-B
(27.6%), and 2 transitional pre-B (3.4%).
3.1.2. B-Cell ALL. Four cases with L3 morphology by the
FAB criteria were classiﬁed as B-cell ALL. All of them were
males with ages 5, 6, 9, and 13 years. The blasts were CD19+,
CD22+ in all cases and showed dimly expression of CD10.
CD45 was bright, with HLA-DR positivity in all cases. The
surface light chain immunoglobin expressed was Kappa in
one case and lambda in 3 cases. The leukemic cells were
CD34− and TdT− in all cases.
3.2. T-Cell-Lineage ALLs. Fifty nine children with T-cell ALL
werestudied.Therewere44maleand15female(male/female
ratio 2.9 3:1 )w i t ha g e sr a n g i n gf r o m0 . 5t o1 7y e a r sa n d
median age of 9 years.
Based on their reactivity with various anti-T-cell mon-
oclonal antibodies (Table 3) ,a l lt e s t e dT - c e l lA L Lc e l l sh a v e
surface CD7 and cytoplasmic CD3 (cCD3) antigens. CD5
was found in 98.2% cases and 70.5% express TdT. CD1a,
surface CD3, and CD4 are detected in about 80% to 83% of
cases. CD10 was found in 10 cases (21.3%) and absent in 37
(78.7%) of 47 T-cell ALLs cases tested for CD10. Except for
2 cases, none of the B-cell associated antigens was expressed
on any T-cell ALLs cases.
Myeloid antigen expression CD13 and/or CD33 was
examined, and 33.9% of cases tested positive for at least one
of the two markers, more frequently CD13 than CD33, and
two cases expressed the two myeloid antigens.
The immunologic subtypes, deﬁned according to the
expression of CD1a and CD3, were as follows: 3.6% pro-T,
80.4% common thymocyte, and 16.1% mature thymocyte.
3.3. CD10 Expression. The correlation of CD10 positivity
with age, leukocyte count at presentation, gender, and FAB
morphology at presentation was analyzed (Table 4). CD10
expression was found in 197 cases of pB-ALL (91.2%) and




than 10 years and have a high leukocyte count (P,n o t
signiﬁcant).
CD10 positivity was less common in T cell lineage and
was associated with female sex and lower leukocyte count.
ThelackofCD10incasesofTcellALLwassigniﬁcantly(P =
.038) associated with patients between 1 and 10 years.
3.4. Lineage Heterogeneity. Lineage heterogeneity was found
in both B-cell and T-cell lineage ALL with 144 (52.4%)
cases having one or two myeloid associated antigens (CD13,
CD33) expressed on their blasts cells. Most of them were of
pB lineage (n = 124), T-lineage about (n = 20). The most
common antigen expressed was the CD13 marker which was
present on 100/216 (46.3%) pB-cell ALL and 13/59 (22%)
T-cell ALL cases.
In nine cases (3.3%) lymphoid antigens (CD7, CD19,
and CD22) were expressed. Two T-cell ALL patients’ cells
expressedCD19orCD22 andcellsofsevenpB-cellALLcases
expressed CD7. The leukemic blast of two pB-cell ALL cases
expressed also CD13 and CD33 with CD7.
4. Discussion and Conclusion
The present work gives the ﬁrst large series of unselected
acute lymphoblastic Leukemia, providing an idea about the
distribution of ALL subtype in Moroccan children. Almost
the majority of children with ALL in Morocco are treated
at pediatric centers (Onco-haematology-Pediatric services of
University Hospital of Rabat and Casablanca) [6, 7], and
about 92% had a three color cytometric immunophenotyp-
ing performed at the National Hygiene Institute laboratory.
Immunophenotyping was used in order to analyze retro-
spectively 279 children with acute lymphoblastic leukemia.
The panel of markers proposed considers two steps; it should
lead to cost saving without loss of valuable information [9].
With the ﬁrst panel we were able to identify the lineage
of over 97% of childhood acute leukemia. Only less than
3% were assigned to deﬁnite lineage after staining with the
second panel.4 International Journal of Pediatrics
Table 2: Patients’ characteristics.
Features All patients (n = 275) T-cell ALL (n = 59) pB-cell ALL (n = 216) P-value
Age at diagnosis (y)
Median 7 9 6
Range 0.5–17 0.5–17 0.5–17
.048‡
<1 6 (2.18%) 1 (1.69%) 5 (2.31%)
1–10 184 (66.91%) 32 (54.24%) 152 (70.37%)
>10 85 (39.91%) 26 (44.07%) 59 (27.31%)
Gender .008‡
M 161 (58.55%) 44 (57.63%) 117 (54.17%)
F 114 (41.45%) 15 (25.42%) 99 (45.83%)
Sex ratio (M/F) 1.41 : 1 2.93 : 1 1.18 : 1
FAB subtype n (%) .85
L1 144 (52.36%) 34 (57.63%) 110 (50.93%)
L2 101 (36.73%) 22 (37.23%) 79 (36.57%)
NS 30 (10.91%) 3 (5.08%) 27 (12.50%)
Leukocyte count (×109/L)
Median 20.14 116 11.38
Range 1–830 1.5–718 1–830
<.0001‡
<50 178 (94.96%) 16 (27.12%) 162 (75.35%)
>50 96 (35.05%) 43 (72.88%) 53 (24.65%)
CNS disease∗∗ 4/218 (1.83%) 2/45 (4.44%) 2/173 (1.16%) .42
Mediastinum∗∗ 35/218 (16.05%) 28/45 (62.22%) 7/173 (4.05%) <.0001‡
ALL: acute lymphoblastique leukaemia, F: female, M: male, Y: year, CNS: central nervous system, NS: not speciﬁed.
∗Mature B-cell ALL excluded.
∗∗Cases with completed data.
‡P ≤ .05 (statistically signiﬁcant).
The relative frequencies of immunological subtypes in
this study are very similar to that reported by the developed
countriesofEuropeandUSA,exceptforthehigherfrequency
of T-ALL (21.15%) [15–19]. One study carried out on
100 Moroccan paediatric patients showed a diﬀerence in
the incidence of T-ALL [20]; the relative incidence of T-
ALL is decreasing from 38% to 21%. The absence at that
time of a system of immunophenotyping referrals and the
small number of cases analyzed, could explain the diﬀerence
in T-ALL incidence observed. In the present study we
took advantage of the recent strategy of Acute Leukemia
diagnosis in Morocco. Importantly, the frequency of T-ALL
observed did not diﬀer signiﬁcantly when we include the
cases diagnosed after the study period.
As it has been described in children [9, 14], the majority
of cases were from pB-ALL (78.5%) with the dominance of
early pre-B phenotype (69% of pB-ALL), followed by pre-
B in 27.6% and Transitional pre-B in 3.4%, with typical
peak between 3 and 5 year. The signiﬁcantly higher incidence
of CD10+ pB-ALL (197/275, 71.6%) observed was like
that observed in developed centers [14, 21, 22]. In T-
cell ALL subgroup, with 80.4%, there is an excess of the
common thymocyte subtype displaying reactivity with CD1a
ascomparedwiththefrequencyreportedbyothers[9,14,23,
24].
We conﬁrmed the close association between T-cell phe-
notype with older age, male gender, mediastinal mass, and
higher leukocyte count [1, 2, 14].
Data concerning the antigen expression for each class
of ALL showed as has been reported in children in various
developing and developed countries [9, 21, 24–27], every
case of B cell lineage ALL expressed CD19, CD22, and
CD79a. Cytoplasmic CD3, CD5, and CD7 were the most
sensitive antigens for the T-cell lineage ALL. However,
the results of the detailed immunologic markers analysis,
underlinesomediﬀerenceofpatternofimmunologicmarker
expression of T-cell ALL. They show that frequencies of
CD1a, surface CD3, and CD4 are higher than generally
observed (less than 45%) [9], and the expression of TdT is
observed in fewer cases (70.5%) than reported in previous
studies, more than 90% [9, 24].
CD10 expression was detected in 197 cases (91.2%)
of the 216 pB-ALL cases and in 10 T-ALL cases (21.3%)
of the 47 cases tested for this antigen. Cases of pB-ALL
having the CD10 expression had lower leukocyte count
and the majority of cases (141/216) were between 1 to
10 years of age (P not signiﬁcant). CD10+ T-ALL cases
were characterized by lower leucocytes count in female
sex (P not signiﬁcant) and older age. Studies of the
prognostic signiﬁcance of CD10 expression in ALL haveInternational Journal of Pediatrics 5
Table 3: Immunophenotypic proﬁles of 275 de novo acute lymphoblastic leukaemia.∗
Markers T-cell ALL (n = 59) pB-cell ALL (n = 216)
∗∗
CD1a+ 45/56 (80.4) —
sCD3+ 49/59 (83.1) 0/216 (0.0)
cCD3+ 57/57 (100) 0/216 (0.0)
CD4+ 42/51 (82.4) —
CD5+ 54/55 (98.2) —
CD7+ 59/59 (100) 7/216 (3.2)
CD8+ 32/52 (61.5) —
CD10+ 10/47 (21.3) 197/216 (91.2)
cyCD79a+ 0/48 (0.0) 162/162 (100)
CD19+ 1/59 (1.7) 216/216 (100)
CD20+ 0/8 (0.0) 26/48 (54.2)
CD22+ 1/47 (2.1) 216/216 (100)
CyIg+ — 18/58 (31.0)
SIg+ — 2/58 (3.5)
TdT+ 31/44 (70.5) 142/158 (89.8)
CD34+ 25/59 (42.4) 160/216 (74.1)
HLA-DR+ 4/39 (10.3) 152/155 (98.1)
CD13+ 13/59 (22) 100/216 (46.3)
CD33+ 9/49 (15.3) 75/216 (34.7)
CD13+,CD33+ 2/59 (3.4) 51/216 (23.6)
CD13−,CD33+ 7/59 (11.9) 24/216 (11.1)
CD13+,CD33− 11/59 (18.6) 49/216 (22.7)
CD13+ and/or CD33+ 20/59 (33.9) 124/216 (57.4)
CD13−,C D 3 3 − 39/59 (66.1) 92/216 (42.6)
CD45+ 59/59 (100) 187/216 (87)
ALL: acute lymphoblastique leukaemia, −: not applicable, MPO: myeloperoxidase, TdT: terminal deoxynucleotidyl transferase, cy: cytoplasmique, s: surface,
+: positive, −: negative, Ig: immunoglobulin.
∗Result are given as number positive/number tested (% positive).
∗∗Mature B-cell ALL excluded.
Table 4: Clinical and biological features according to CD10 expression in children with ALL.
No. of patients (%)
pB-cell ALL (n = 216) T-cell ALL (n = 47)
Features Total of patients CD10− CD10+ P value CD10− CD10+ P value
Gender .92 .24
F 113 9 (9.09) 90 (90.91) 9 (64.29) 5 (35.71)
M 150 10 (8.55) 107 (91.45) 28 (84.85) 5 (15.15)
Leukocyte count (×109/L) .31 .81
<50 177 12 (4.71) 150 (92.59) 11 (73.33) 4 (26.67)
>50 85 7 (13.21) 46 (86.79) 26 (81.25) 6 (18.75)
FAB subtype .67 .89
L1 135 10 (9.09) 100 (90.91) 19 (76.00) 6 (24.00)
L2 98 5 (6.33) 74 (93.67) 15 (78.95) 4 (21.05)
Age (Y) .27 .038‡
<1 6 0 (0.00) 5 (100) 0 (0.00) 1 (100)
1–10 147 11 (7.24) 141 (92.76) 20 (90.91) 2 (9.09)
>10 83 8 (13.56) 51 (86.44) 17 (70.83) 7 (29.17)
ALL: acute lymphoblastic leukaemia, F: female, M: male, Y: year.
‡P ≤ .05 (statistically signiﬁcant).6 International Journal of Pediatrics
showed the CD10 expression in childhood B lineage ALL
is associated with several favorable presenting features but
is not an independent prognostic factor [13, 28–30]. In
T cell lineage, the expression of CD10 was independently
associatedwithfavorableclinicaloutcome[14,23].However,
for the larger subgroup of patients with T-lineage ALL,
CD10expressionhasnoindependentprognosticsigniﬁcance
[30].
Aberrant expression of myeloid antigens (MyAgs) on
acute lymphoblastic leukemia cells is a well-documented
phenomenon and has no prognostic or therapeutic implica-
tions [15, 31–33] but can be used for monitoring MRD [32].
The myeloid-associated antigens CD13/CD33 used in the
currentstudywerethemostcommonlyexpressedinchildren
ALL cases, and their incidence should be representative of
overall MyAgs expression [15]. In the present study, MyAgs
expression occurs in 52.7% of all cases (57.4% of pB cell
ALL and 33.9% of T-ALL). This frequency is higher than
in previous studies (between 6% and 35%) [15, 28, 31, 33];
however it is comparable to those reported by Khalidi et
al. [21]. The diﬀerences observed are probably due to the
criteria used to deﬁne a “percent positive” cell and the
number of antigens tested [15, 21].
We can draw the following conclusions from our
study: (1) we conﬁrm the excellent practicability of the
two immunophenotyping steps strategy for classiﬁcation of
ALLs, especially in countries with limited resources; (2)
the distribution of ALLs in Moroccan children is similar
with the general distribution pattern in developed countries,
except for the high frequency of T-ALL phenotype; (3) the
phenotypic proﬁle of our patients is close to those reported
inliteratureforB-lineageALLs.FortheT-cellALLsubgroup,
the blast cells express more CD1a, surface CD3, and CD4
while expressing less TdT. The high frequency of CD1a
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